Latest Headlines

Latest Headlines

The curious case of Xoma.com

On Thursday, all of the content on Xoma's website was replaced by a single phrase.

Xoma drug fails to beat out a placebo in PhII osteoarthritis study

After the markets closed on Tuesday, Xoma put out the word that its main pipeline asset, gevokizumab (Xoma 052) flunked a Phase II program for erosive osteoarthritis of the hand, ending any shot it had at a broad pivotal study in that indication.

Xoma staffers form biotech startup to advance blood pressure med

Xoma has chosen a new home for a fixed-dose combination product for reducing blood pressure, transferring the asset to the startup Symplmed Pharmaceuticals in exchange for equity in the new company and up to double-digit royalties on potential U.S. sales.

Xoma hunts for marketing partner as blood pressure med clears PhIII

Xoma says it hit its primary endpoint in a late-stage test of a blood pressure combo including Servier's perindopril, setting the stage for an NDA as the biotech goes hunting for a partner to market the therapy in the U.S.

CMC expands biologics capacity with plant buy

CMC Biologics is a buying Xoma's large-scale manufacturing facility in the Bay Area, giving the company a regional foothold in one of biotech's hotbeds.

Computer-based discovery biotech from Israel lands in Bay Area

Tel Aviv-based Compugen has opened shop in a promised land of biotech, South San Francisco.

Xoma axing 84 jobs to save dollars for lead drug

Xoma ($XOMA) has rung in 2012 with major cutbacks and organizational changes. The Berkeley, CA-based biotech company aims to axe 84 jobs or 34% of its work force by the end of the first quarter with

Beleaguered Xoma CEO Engle turns in his walking papers

About 5 months after Xoma's ($XOMA) lead drug flamed out in a crucial mid-stage study, Steve Engle has resigned as CEO and chairman of the beleaguered biotech. The company quickly tapped board member

Xoma shares blitzed after lead drug flunks key diabetes study

Xoma's lead drug failed a Phase IIb diabetes study and news of the debacle quickly sent its stock into a tailspin, wiping out 37% of the biotech's market value in minutes yesterday evening. The trial

Xoma snags $505 million pact on its top drug prospect

Xoma announced its long-anticipated licensing pact on the promising anti-inflammatory drug 052 this morning, snagging a $505 million pact and fueling a further surge in its sizzling share price. But